The InfectoPharm Group is engaged in more than 30 international partnerships and is increasingly expanding into non-EU markets. Subsidiaries of the group in Austria and Italy operate with a selected part of the portfolio. The InfectoPharm Group further consists of two strategically matching German subsidiaries: Pädia GmbH offers a distinct pediatric OTC portfolio with about 25 prescription-free pharmaceuticals and Beyvers GmbH in Berlin is an internationally known full service-supplier for pharmaceuticals and cosmetics.
With more than 350 employees, the group generates annual sales of around 250 million euros (2022) and an average growth rate of 15 percent. InfectoPharm regularly receives awards from the medical profession, such as the “Golden Tablet” or currently as “Most Crisis-Proof Employer” from Creditreform.
In 2017, the London Stock Exchange Group (LSEG) listed us as one of 1,000 Companies to Inspire Europe and included us in its annual report on outstanding medium-sized companies in Europe.
Furthermore, InfectoPharm offers an interdisciplinary educational and consulting medical service in Germany. The consilium service brand operates without any commercial interests. It is based on lifelong learning and the sharing of knowledge in an ongoing exchange amongst practitioners, partners and health-care professionals.
Countering bacterial resistance
Infections with resistant germs are a serious issue in hospitals around the globe. A special branch of InfectoPharm is dedicated to developing highly effective antibiotics, thus supporting hospital physicians in antibiotic stewardship and difficult to treat infections. These highly effective antibiotics used in hospitals form an important step toward a more patient-friendly therapy.
Watch the InfectoPharm Video (4:30 minutes).